The Severity of Visceral Leishmaniasis Correlates with Elevated Levels of Serum IL-6, IL-27 and sCD14

PLoS Neglected Tropical Diseases

Volumn 10, Issue 1, 2016, Pages

  dos Santos, Priscila L ^a   de Oliveira, Fabrícia A ^a   Santos, Micheli Luize B ^a   Cunha, Luana Celina S ^a   Lino, Michelle T B ^a   de Oliveira, Michelle F S ^a   Bomfim, Manuela O M ^a   Silva, Angela Maria ^a   de Moura, Tatiana R ^a   de Jesus, Amélia R ^a,b   Duthie, Malcolm S ^c   Reed, Steven G ^c   de Almeida, Roque P ^a,b  

^a FEDERAL UNIVERSITY OF SERGIPE   (Brazil)

^b Instituto de Investigacao em Imunologia   (Brazil)

^c Infectious Diseases Research Institute (IDRI)   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; CD14 ANTIGEN; FATTY ACID BINDING PROTEIN 2; GAMMA GLUTAMYLTRANSFERASE; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 27; INTERLEUKIN 6; MACROPHAGE MIGRATION INHIBITION FACTOR; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; EOSINOPHIL COUNT; FEMALE; HEMATOLOGICAL PARAMETERS; HUMAN; MALE; NEUTROPHIL COUNT; SEROLOGY; THROMBOCYTE COUNT; VISCERAL LEISHMANIASIS; ADOLESCENT; BLOOD; CHILD; CROSS-SECTIONAL STUDY; INFANT; LEISHMANIA INFANTUM; MIDDLE AGED; PARASITOLOGY; PATHOLOGY; PHYSIOLOGY; PRESCHOOL CHILD; YOUNG ADULT;

ADOLESCENT; ADULT; ANTIGENS, CD14; CHILD; CHILD, PRESCHOOL; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; INFANT; INTERLEUKIN-27; INTERLEUKIN-6; LEISHMANIA INFANTUM; LEISHMANIASIS, VISCERAL; MALE; MIDDLE AGED; YOUNG ADULT;

EID: 84961382890     PISSN: 19352727     EISSN: 19352735     Source Type: Journal    
DOI: 10.1371/journal.pntd.0004375     Document Type: Article

References (57)

1. Alvar J, Vélez ID, Bern C, Herrero M, Desjeux P, Cano J, et al. Leishmaniasis Worldwide and Global Estimates of Its Incidence.Plos one. 2012; 7: e35671. doi: 10.1371/journal.pone.0035671 22693548
2. Organization WH. Control of the leishmaniasis: report of a meeting of the WHO Expert Committee on the Control of Leishmaniases, Geneva, 22–26 March 2010.WHO technical report series. 2010; 949.
3. Badaro R, Jones TC, Carvalho EM, Sampaio D, Reed SG, Barral A, et al. New perspectives on a subclinical form of visceral leishmaniasis.J Infect Dis. 1986; 154: 1003–1011. 3782864
4. Sampaio MJ, Cavalcanti NV, Alves JG, Filho MJ, Correia JB, Risk factors for death in children with visceral leishmaniasis.PLoS Negl Trop Dis. 2010; 4: e877. doi: 10.1371/journal.pntd.0000877 21072238
5. Bacellar O, M, Carvalho E, Imunopatogênese da Leishmaniose Visceral.Gazeta Médica da Bahia. 2005; 75.
6. Costa AS, Costa GC, Aquino DM, Mendonca VR, Barral A, Barral-Netto M, et al. Cytokines and visceral leishmaniasis: a comparison of plasma cytokine profiles between the clinical forms of visceral leishmaniasis.Mem Inst Oswaldo Cruz. 2012; 107: 735–739. 22990961
7. Costa DL, Rocha RL, Carvalho RM, Lima-Neto AS, Harhay MO, Costa CH, et al. Serum cytokines associated with severity and complications of kala-azar.Pathog Glob Health. 2013; 107: 78–87. doi: 10.1179/2047773213Y.0000000078 23683334
8. Duthie MS, Guderian J, Vallur A, Bhatia A, Lima dos Santos P, Vieira de Melo E, et al. Alteration of the serum biomarker profiles of visceral leishmaniasis during treatment.Eur J Clin Microbiol Infect Dis. 2014; 33: 639–649. doi: 10.1007/s10096-013-1999-1 24173820
9. Gama ME, Gomes CM, Silveira FT, Laurenti MD, Goncalves Eda G, Silva AR, et al. Severe visceral leishmaniasis in children: the relationship between cytokine patterns and clinical features.Rev Soc Bras Med Trop. 2013; 46: 741–745. doi: 10.1590/0037-8682-0203-2013 24474016
10. Gautam S, Kumar R, Maurya R, Nylen S, Ansari N, Rai M, et al. IL-10 neutralization promotes parasite clearance in splenic aspirate cells from patients with visceral leishmaniasis.J Infect Dis. 2011; 204: 1134–1137. doi: 10.1093/infdis/jir461 21881130
11. Hailu A, van der Poll T, Berhe N, Kager PA, Elevated plasma levels of interferon (IFN)-gamma, IFN-gamma inducing cytokines, and IFN-gamma inducible CXC chemokines in visceral leishmaniasis.Am J Trop Med Hyg. 2004; 71: 561–567. 15569785
12. Khoshdel A, Alborzi A, Rosouli M, Taheri E, Kiany S, Javadian MH, . Increased levels of IL-10, IL-12, and IFN- in patients with visceral leishmaniasis.Braz J Infect Dis. 2009; 13: 44–46. 19578629
13. Peruhype-Magalhaes V, Martins-Filho OA, Prata A, Silva Lde A, Rabello A, Teixeira-Carvalho A, et al. Immune response in human visceral leishmaniasis: analysis of the correlation between innate immunity cytokine profile and disease outcome.Scand J Immunol. 2005; 62: 487–495. 16305646
14. Peruhype-Magalhaes V, Martins-Filho OA, Prata A, Silva Lde A, Rabello A, Teixeira-Carvalho A, et al. Mixed inflammatory/regulatory cytokine profile marked by simultaneous raise of interferon-gamma and interleukin-10 and low frequency of tumour necrosis factor-alpha(+) monocytes are hallmarks of active human visceral Leishmaniasis due to Leishmania chagasi infection.Clin Exp Immunol. 2006; 146: 124–132. 16968407
15. Nylen S, Sacks D, Interleukin-10 and the pathogenesis of human visceral leishmaniasis.Trends Immunol. 2007; 28: 378–384. 17689290
16. Ansari NA, Kumar R, Gautam S, Nylen S, Singh OP, Sundar S, et al. IL-27 and IL-21 are associated with T cell IL-10 responses in human visceral leishmaniasis.J Immunol. 2011; 186: 3977–3985. doi: 10.4049/jimmunol.1003588 21357266
17. Hunter CA, Kastelein R, Interleukin-27: balancing protective and pathological immunity.Immunity. 2012; 37: 960–969. doi: 10.1016/j.immuni.2012.11.003 23244718
18. Andrade TM, Carvalho EM, Rocha H, Bacterial infections in patients with visceral leishmaniasis.J Infect Dis. 1990; 162: 1354–1359. 2230265
19. Ramachandran G, Gram-positive and gram-negative bacterial toxins in sepsis: a brief review.Virulence. 2014; 5: 213–218. doi: 10.4161/viru.27024 24193365
20. Santos-Oliveira JR, Regis EG, Leal CR, Cunha RV, Bozza PT, Da-Cruz AM, Evidence that lipopolisaccharide may contribute to the cytokine storm and cellular activation in patients with visceral leishmaniasis.PLoS Negl Trop Dis. 2011; 5: e1198. doi: 10.1371/journal.pntd.0001198 21765960
21. Saúde. BMd. Manual de vigilância e controle da leishmaniose visceral.Brasília: Editora do Ministério da Saúde. 2006.
22. Skraba CM, de Mello TF, Pedroso RB, Ferreira EC, Demarchi IG, Aristides SM, et al. Evaluation of the reference value for the Montenegro skin test.Rev Soc Bras Med Trop. 2015; 48: 437–444. doi: 10.1590/0037-8682-0067-2015 26312935
23. Belo VS, Struchiner CJ, Barbosa DS, Nascimento BW, Horta MA, da Silva ES, et al. Risk Factors for Adverse Prognosis and Death in American Visceral Leishmaniasis: A Meta-analysis.PLoS Negl Trop Dis. 2014; 8: e2982. doi: 10.1371/journal.pntd.0002982 25058582
24. Diro E, Lynen L, Ritmeijer K, Boelaert M, Hailu A, van Griensven J, Visceral Leishmaniasis and HIV coinfection in East Africa.PLoS Negl Trop Dis. 2014; 8: e2869. doi: 10.1371/journal.pntd.0002869 24968313
25. Belo VS, Werneck GL, Barbosa DS, Simoes TC, Nascimento BW, da Silva ES, et al. Factors associated with visceral leishmaniasis in the americas: a systematic review and meta-analysis.PLoS Negl Trop Dis. 2013; 7: e2182. doi: 10.1371/journal.pntd.0002182 23638203
26. Leite AI, Araújo LB, Leishmaniose visceral: aspectos epidemiológicos relacionados aos óbitos em Mossoró-RN.Rev Patol Tropi. 2013; 42: 301–308.
27. de Araujo VE, Morais MH, Reis IA, Rabello A, Carneiro M, Early clinical manifestations associated with death from visceral leishmaniasis.PLoS Negl Trop Dis. 2012; 6: e1511. doi: 10.1371/journal.pntd.0001511 22347514
28. Costa CH, Pereira HF, Araujo MV, Visceral leishmaniasis epidemic in the State of Piaui, Brazil, 1980–1986].Rev Saude Publica. 1990; 24: 361–372. 2101528
29. Liu L, Wang L, Zhao Y, Wang Y, Wang Z, Qiao Z, Testosterone attenuates p38 MAPK pathway during Leishmania donovani infection of macrophages.Parasitol Res. 2006; 99: 189–193. 16547729
30. Travi BL, Osorio Y, Melby PC, Chandrasekar B, Arteaga L, Saravia NG, Gender is a major determinant of the clinical evolution and immune response in hamsters infected with Leishmania spp.Infect Immun. 2002; 70: 2288–2296. 11953362
31. Maegraith B, Pathological processes in malaria.Trans R Soc Trop Med Hyg. 1948; 41: 687–704. 18865438
32. Barral-Netto M, Badaro R, Barral A, Almeida RP, Santos SB, Badaro F, et al. Tumor necrosis factor (cachectin) in human visceral leishmaniasis.J Infect Dis. 1991; 163: 853–857. 1901333
33. Clark IA, Alleva LM, Mills AC, Cowden WB, Pathogenesis of malaria and clinically similar conditions.Clin Microbiol Rev. 2004; 17: 509–539, table of contents. 15258091
34. Costa CH, Werneck GL, Costa DL, Holanda TA, Aguiar GB, Carvalho AS, et al. Is severe visceral leishmaniasis a systemic inflammatory response syndrome? A case control study.Rev Soc Bras Med Trop. 2010; 43: 386–392. 20802936
35. Goto H, Prianti M, Immunoactivation and immunopathogeny during active visceral leishmaniasis.Rev Inst Med Trop Sao Paulo. 2009; 51: 241–246. 19893975
36. Caldas A, Favali C, Aquino D, Vinhas V, van Weyenbergh J, Brodskyn C, et al. Balance of IL-10 and interferon-gamma plasma levels in human visceral leishmaniasis: implications in the pathogenesis.BMC Infect Dis. 2005; 5: 113. 16364177
37. Carvalho EM, Bacellar O, Brownell C, Regis T, Coffman RL, Reed SG, Restoration of IFN-gamma production and lymphocyte proliferation in visceral leishmaniasis.J Immunol. 1994; 152: 5949–5956. 8207220
38. Bacellar O, Brodskyn C, Guerreiro J, Barral-Netto M, Costa CH, Coffman RL, et al. Interleukin-12 restores interferon-gamma production and cytotoxic responses in visceral leishmaniasis.J Infect Dis. 1996; 173: 1515–1518. 8648233
39. Janeway CA, Jr.The immunobiology of the T cell response to Mls locus disparate stimulator cells.Curr Top Microbiol Immunol. 1988; 137: 171–176. 2970945
40. de Oliveira FA, Vanessa Oliveira Silva C, Damascena NP, Passos RO, Duthie MS, Guderian JA, et al. High levels of soluble CD40 ligand and matrix metalloproteinase-9 in serum are associated with favorable clinical evolution in human visceral leishmaniasis.BMC Infect Dis. 2013; 13: 331. doi: 10.1186/1471-2334-13-331 23870715
41. Belkhelfa M, Rafa H, Medjeber O, Arroul-Lammali A, Behairi N, Abada-Bendib M, et al. IFN-gamma and TNF-alpha Are Involved During Alzheimer Disease Progression and Correlate with Nitric Oxide Production: A Study in Algerian Patients.J Interferon Cytokine Res. 2014.
42. Wang SM, Liao YT, Hu YS, Ho TS, Shen CF, Wang JR, et al. Immunophenotype expressions and cytokine profiles of influenza A H1N1 virus infection in pediatric patients in 2009.Dis Markers. 2014; 2014: 195453. doi: 10.1155/2014/195453 24696530
43. Sabat R, Grutz G, Warszawska K, Kirsch S, Witte E, Wolk K, et al. Biology of interleukin-10.Cytokine Growth Factor Rev. 2010; 21: 331–344. doi: 10.1016/j.cytogfr.2010.09.002 21115385
44. Verma S, Kumar R, Katara GK, Singh LC, Negi NS, Ramesh V, et al. Quantification of parasite load in clinical samples of leishmaniasis patients: IL-10 level correlates with parasite load in visceral leishmaniasis.PLoS One. 2010; 5: e10107. doi: 10.1371/journal.pone.0010107 20404924
45. Silva JM, Zacarias DA, de Figueiredo LC, Soares MR, Ishikawa EA, Costa DL, et al. Bone marrow parasite burden among patients with New World kala-azar is associated with disease severity.Am J Trop Med Hyg. 2014; 90: 621–626. doi: 10.4269/ajtmh.13-0376 24615127
46. Wynick C, Petes C, Gee K, Interleukin-27 Mediates Inflammation During Chronic Disease.J Interferon Cytokine Res. 2014.
47. Aderka D, Le JM, Vilcek J, IL-6 inhibits lipopolysaccharide-induced tumor necrosis factor production in cultured human monocytes, U937 cells, and in mice.J Immunol. 1989; 143: 3517–3523. 2584704
48. Diehl S, Anguita J, Hoffmeyer A, Zapton T, Ihle JN, Fikrig E, et al. Inhibition of Th1 differentiation by IL-6 is mediated by SOCS1.Immunity. 2000; 13: 805–815. 11163196
49. Diehl S, Rincon M, The two faces of IL-6 on Th1/Th2 differentiation.Mol Immunol. 2002; 39: 531–536. 12431386
50. Bacellar O, Lessa H, Schriefer A, Machado P, Ribeiro de Jesus A, Dutra WO, et al. Up-regulation of Th1-type responses in mucosal leishmaniasis patients.Infect Immun. 2002; 70: 6734–6740. 12438348
51. Xu C, Chang A, Hack BK, Eadon MT, Alper SL, Cunningham PN, TNF-mediated damage to glomerular endothelium is an important determinant of acute kidney injury in sepsis.Kidney Int. 2014; 85: 72–81. doi: 10.1038/ki.2013.286 23903370
52. Kinra P, Dutta V, Serum TNF alpha levels: a prognostic marker for assessment of severity of malaria.Trop Biomed. 2013; 30: 645–653. 24522135
53. Landmann R, Knopf HP, Link S, Sansano S, Schumann R, Zimmerli W, Human monocyte CD14 is upregulated by lipopolysaccharide.Infect Immun. 1996; 64: 1762–1769. 8613389
54. Tuon FF, Fernandes ER, Duarte MI, Amato VS, Expression of TLR2 and TLR4 in lesions of patients with tegumentary American leishmaniasis.Rev Inst Med Trop Sao Paulo. 2012; 54: 159–163. 22634888
55. Landmann R, Reber AM, Sansano S, Zimmerli W, Function of soluble CD14 in serum from patients with septic shock.J Infect Dis. 1996; 173: 661–668. 8627030
56. Karima R, Matsumoto S, Higashi H, Matsushima K, The molecular pathogenesis of endotoxic shock and organ failure.Mol Med Today. 1999; 5: 123–132. 10203736
57. Gluck T, Silver J, Epstein M, Cao P, Farber B, Goyert SM, Parameters influencing membrane CD14 expression and soluble CD14 levels in sepsis.Eur J Med Res. 2001; 6: 351–358. 11549517